(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Traumatic Brain Injury
Explore 83 assets in Traumatic Brain Injury →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of Texas Southwestern Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06062628CT.gov Ketamine in Severe Traumatic Brain Injury | — | Recruiting | — | — | — |
NCT06429657CT.gov Ketamine for Sedation in Severe Traumatic Brain Injury | — | Suspended | — | — | — |
NCT06228391CT.gov Ketamine Treatment for PTSD and MDD in TBI | — | Not Yet Recruiting | — | — | — |
NCT05097261CT.gov Ketamine in Acute Brain Injury Patients. | — | Recruiting | — | — | — |
NCT02501941CT.gov Spreading Depolarization and Ketamine Suppression | — | Completed | — | — | — |
NCT04057989CT.gov Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related Pain | — | Completed | — | — | — |
NCT00556387CT.gov Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection | — | Withdrawn | — | — | — |
NCT00437814CT.gov Effect of Ketamine (Ketalar) on Intracranial Pressure | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | University of Texas Southwestern Medical Center | Approved | BB · 66 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Lacto-Flavin | POLYSAN Scientific & Technological Pharmaceutical Company | P3 | BB |
| Fentanyl | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Serostim | Anhui Provincial Hospital | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →